Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification

Abstrakt

Authors presented a case report of male patient suffering with advanced lung adenocarcinoma exhibiting mutioned genetic abnormalities having got more than 3 years duration of remission on erlotinib therapy.

Klíčová slova

• NSCLC
• adenocarcinoma
• erlotinib
• KRAS mutation
• EGFR amplification